World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization: Geneva; 1999.
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–46.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31.
Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. The epidemiology of type 2 diabetes mellitus in Greek adults: the ATTICA study. Diabet Med. 2005;22:1581–8.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 2006.
Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32.
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.
American Diabetes Association. Economic costs of diabetes in the US in 2007. American Diabetes Association: Diabetes Care 2008, 31.
Migdalis I, Rombopoulos G, Hatzikou M, Manes C, Kypraios N, Tentolouris N. The cost of managing type 2 diabetes mellitus in Greece: a retrospective analysis of 10-year patient level data “The HERCULES Study”. Int J Endocrinol. 2015;2015:520759.
International Diabetes Federation. Global guideline for type 2 diabetes. 2012.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
Canadian Diabetes Association. Targets for glycemic control. Can J Diabetes. 2013;37:S302–3.
Foos V, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ. 2015;18:420–32.
Jeon HJ, Oh TK. Comparison of vildagliptin–metformin and glimepiride–metformin treatments in type 2 diabetic patients. Diabetes Metab J. 2011;35:529–35.
Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157–66.
Clarke P, Gray A, Briggs A. Al. E: a model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–59.
Viriato D, Calado F, Gruenberger J-B, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ. 2014;17:499–507.
International Diabetes Federation. IDF Diabetes Atlas, 6th Edition. 2013.
Hellenic Diabetes Association. Guidelines for the management of the diabetic patient. 2013.
NICE. Guide to the methods of technology appraisal 2013. 2013.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.
Ministry of Health. Positive reimbursement list, Governmental Gazette 2336B. 2014.
Ministry of Health. Unified Regulation for Health Care Benefits, Government Gazette 3054. 2012.
National Organization for health care services provision. Amendment of unified regulation for health care benefits, Protocol No 22473. 2013.
Ministry of Health. Diagnosis related groups and related tariffs, Governmental Gazette 946. 2012.
Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M, Alexopoulosi D. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol. 2005;46:212–21.
http://www.statistics.gr. Accessed July 2015.
Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J Clin Hypertens (Greenwich). 2007;9:751–9.
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340–9.
Manns B, Meltzer D, Taub K, Donaldson C. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ. 2003;12:949–58.
Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008;11:478–86.
Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523–34.
Smith D, Gravelle H. the practice of discounting economic evaluation of health care interventions. CHE Technical Paper Series 19. 2000.
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45:S5–12.
Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complicat. 2015;29:529–33.
Jones S, Castell C, Goday A, Smith HT, Nicolay C, Simpson A, Salaun-Martin C. Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study. Clinicoecon Outcomes Res. 2012;4:383–93.